Trials / Completed
CompletedNCT03098589
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
Revlimid® Capsules Drug Use-results Surveillance Relapsed or Refractory Adult T-cell Leukemia Lymphoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,149 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients with relapsed or refractory adult T-cell leukemia lymphoma (hereinafter referred to as relapsed or refractory Adult T-cell Leukemia Lymphoma (ATLL)). 1. Planned registration period 3 years 2. Planned surveillance period 4 years and 6 months after a month after the approval for partial changes in the approved items is granted for relapsed or refractory ATLL
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Revlimid | Revlimid |
Timeline
- Start date
- 2017-05-30
- Primary completion
- 2020-09-18
- Completion
- 2020-09-18
- First posted
- 2017-04-04
- Last updated
- 2025-03-30
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03098589. Inclusion in this directory is not an endorsement.